SAR-443809 

SAR-443809 is a selective alternative complement system inhibitor and monoclonal antibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a K_D of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway^[1].

Human

SAR-443809 (Human FB: 6-500 nM; human FBb: 0.4-30 nM; SAR443809 Fab: 3.7-300 nM; 25°C during assay) 与人 Bb 因子 (K_D = 7.3 nM) 和食蟹猴 Bb 因子 (K_D = 61 nM) 高亲和力结合，且其 Fab 片段与活化的补体旁路途径 C3 转化酶 (C3bBb) 高亲和力结合 (K_D = 0.5 nM)^[1]。
SAR-443809 可通过阻断 C3 和 B 因子的裂解，强效且选择性地抑制人补体旁路途径 (IC₅₀ = 8.47 μg/mL) 与食蟹猴补体旁路途径 (IC₅₀ = 15.72 μg/mL)，且不会抑制经典途径或凝集素途径^[1]。
SAR-443809 (37°C 作用 50 分钟) 可抑制旁路途径介导的兔红细胞溶血，其 IC₅₀ 为 28.45 μg/mL^[1]。
SAR-443809 (37°C 处理 50 分钟) 可抑制旁路途径介导的 C3b 在兔红细胞上的沉积，其表观 IC₅₀ 为 33.8 μg/mL^[1]。
SAR-443809 (100 μg/mL; 30 minutes at 37°C) 可抑制 H 因子缺失的人血清中不受调控的液相 C3 裂解，通过补体旁路途径的自发激活阻止 C3 的消耗^[1]。
SAR-443809 可选择性结合人因子 Bb (EC₅₀ = 30.9 ng/mL)，且对其他受试血浆丝氨酸蛋白酶无特异性结合，其中包括大多数补体系统酶^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SAR-443809 (15 mg/kg；静脉注射/皮下注射；单次给药) 在雌性食蟹猴中可实现补体旁路途径活性的持续性 (≥ 288 hours) 90% 抑制^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

629  [NCBI]

AAH04143.1

Complement Factor B/CFB

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rajagopal V, et al. SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb. Blood Adv. 2023;7(16):4258-4268.  [Content Brief]